Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Cytosorbents Corp on June 2, 2015. The filing details the voting outcomes for four specific proposals submitted by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1 (Election of Directors): All five nominees (Phillip Chan, Al W. Kraus, Edward R. Jones, James Gunton, and Alan D. Sobel) were elected to serve one-year terms. Significant broker non-votes (8,485,960) were recorded for all candidates.
- Proposal 2 (Say-on-Pay): Stockholders approved the advisory vote on executive compensation. Votes cast were 11,118,694 For, 139,894 Against, and 149,963 Abstain.
- Proposal 3 (Frequency of Say-on-Pay): Stockholders approved holding the advisory compensation vote every three years. Votes cast were 10,221,378 for 3 years, 880,732 for 1 year, and 219,462 for 2 years.
- Proposal 4 (Auditor Ratification): Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm. Votes cast were 19,682,979 For, 97,465 Against, and 114,067 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Important Facts for Investors to Verify
- Confirmation that the five elected directors have accepted their positions and will serve the one-year term.
- Verification of the high volume of broker non-votes (8,485,960) and their impact on the effective voting power of beneficial owners.
- Confirmation that the selected auditor, WithumSmith+Brown, PC, has formally accepted the engagement for the 2015 fiscal year.
- Review of the full proxy statement for details on the executive compensation package approved in Proposal 2.